Drug therapy of patients with myocardial infarction as the most important component of a polyclinic stage of cardiorehabilitation

Cover Page

Cite item

Full Text

Abstract

Myocardial infarction (MI) is one of the most common causes of temporary incapacity, disability and mortality in the adult population of developed countries. Despite a trend in recent years to reduce mortality from cardiovascular disease, the indicator remains high in Russia. One of the main conditions to improve immediate and long-term prognosis of patients after MI, is to conduct a comprehensive cardio-rehabilitation, which is an important component of drug therapy. The article presents the characteristics of drug therapy and its influence on the course of post-MI at 5-year follow-up on the basis of "Register of acute MI". As a result of the frequency, VEN-analysis revealed no significant differences in the main groups of drugs prescribed in different periods after acute MI. At the same time it found that patients with unfavorable course of postinfarction period, significantly more often treated with inadequate doses of b-blockers, who were appointed at hospital discharge and then titrated with the annual and 5-year follow-up. The lower frequency of the appointment of vital medicines (based on VEN-analysis) was detected in patients with unfavorable course of postinfarction period as the baseline, and after a year, and 5 years after MI. Installed features of drug use have an impact on the clinical course of postinfarction period and the development of negative cardiovascular events.

About the authors

A. A Garganeeva

Scientific-Research Institute of Cardiology

Email: aag@cardio-tomsk.ru
д-р мед. наук, проф., рук. отд-ния общеклинической кардиологии и эпидемиологии сердечно-сосудистых заболеваний ФГБНУ НИИ кардиологии 634012, Russian Federation, Tomsk, ul. Kievskaia, d. 111a

E. A Kuzheleva

Scientific-Research Institute of Cardiology

Email: snigireva1209@rambler.ru
аспирант отд-ния общеклинической кардиологии и эпидемиологии сердечно-сосудистых заболеваний ФГБНУ НИИ кардиологии 634012, Russian Federation, Tomsk, ul. Kievskaia, d. 111a

E. V Efimova

Scientific-Research Institute of Cardiology

Email: ev@cardio-tomsk.ru
канд. мед. наук, глав. врач клиники ФГБНУ НИИ кардиологии 634012, Russian Federation, Tomsk, ul. Kievskaia, d. 111a

O. V Tukish

Scientific-Research Institute of Cardiology

Email: kitty-lit@yandex.ru
аспирант отд-ния общеклинической кардиологии и эпидемиологии сердечно-сосудистых заболеваний ФГБНУ НИИ кардиологии 634012, Russian Federation, Tomsk, ul. Kievskaia, d. 111a

References

  1. Оганов Р.Г., Масленникова Г.Я. Смертность от сердечно - сосудистых и других хронических неинфекционных заболеваний среди трудоспособного населения в России. Кардиоваскулярная терапия и вторичная профилактика. 2003; 1 (3): 5-7.
  2. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. 2011; 10 (6); прил. 2.
  3. Antman E.M, Anbe D.T, Armstrong P.W et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation 2004; 110: 282-92.
  4. Карпов Ю.А., Аронов Д.М. Кардиологическая реабилитация в России нуждается в коренной реорганизации. Кардиологический вестн. 2010; V (XVII), 2: 5-11.
  5. Аронов Д.М., Бубнова М.Г., Барбараш О.Л. и др. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы: реабилитация и вторичная профилактика. Российские клинические рекомендации. CardioСоматика. 2014; 1 (Прил.).
  6. Кожанова И.Н., Романова И.С., Хапалюк А.В., Степанова М.Д. Основы фармакоэпидемиологического и фармакоэкономического анализа использования лекарственных средств при хронических заболеваниях. Учебно - методическое пособие. Минск: БелМАПО, 2006; с. 5-26.
  7. Gliklich R.E, Dreyer N.A, eds. Registries for Evaluating Patient Outcomes: A User’s Guide. (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under Contract No. HHSA29020050035I TO1.). AHRQ. №07-EHC001-1. Rockville, MD: Agency for Healthcare Research and Quality, 2007; р. 7-15.

Copyright (c) 2015 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies